Hoth Therapeutics, Inc. (HOTH) reported positive pre-clinical research showcasing the potential of HT-ALZ, an Alzheimer's disease therapeutic. The company said the research presents compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment.
Hoth Therapeutics said it remains committed to further research and development of HT-ALZ, including detailed analyses of its effects on microglial activation and brain inflammation. The company said it is optimistic about HT-ALZ's path toward.
Shares of Hoth Therapeutics are up 34% in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.